Pharamcology/Therapeutics Flashcards
Alpelisib + Fulvestrant:
a. Molecular target/Treatment indication
b. Needed prior to initiating therapy
a. Alpelisib targets PIK3CA and used in treatment of metastatic triple-negative breast cancer
b. HbA1c - due to hyperglycemia risk
Most common side effects associated with ALK inhibitors and first/second line therapy:
a. Alectinib
b. Brigatinib
c. Ceritinib
d. Lorlatinib
a. Alectinib - myalgias
b. Brigatinib – pneumonitis (start at a lower dose)
c. Ceritinib - GI toxicities
d. Lorlatinib - hyperlipidemia, personality changes
Opiate Conversions from PO Morphine
a. IV Morphine 1 mg
b. IV Dilaudid 1 mg
c. PO Dilaudid 1 mg
d. Oxycodone 5 mg
Drug, MME Equivalent, Dosing
IV Morphine, 3, 10 mg
IV Dilaudid, 15, 1.5 mg
Hydromorphone PO, 5, 2 mg
Morphine, 1, 10mg
Oxycodone, 1.5, 6.6mg
Tramadol, 0.1, 100mg
NOTE: when switching between different opioids, the calculated dose-equivalent must be reduced to ensure safety by 25-50%